secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2026-09-23T12:15:05+00:00
Accession:  0001193125-26-398561
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept: President of Endocrinology Sean Maduck retires Oct 1; Justin Gunn succeeds
--------------------------------------------------------------------------------

- Sean Maduck resigns as President, Endocrinology, effective Oct 1, 2026; no disagreement cited.
- Justin Gunn appointed President, Endocrinology, assumes role Oct 1; joins Executive Team, reports to CEO.
- Maduck signs consulting agreement at $57k/month through Sept 30, 2027; stock options keep vesting.
- Gunn joined Corcept July 2024 as VP Sales; led sales org for Lifyorli launch; 18 yrs at Gilead.
- Maduck will remain as senior commercial advisor to ensure smooth transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/0001193125-26-398561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/d148256d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-398561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer